Hengrui presents 64 oncology studies at ESMO 2026
Hengrui Pharma presented 64 oncology studies at the ESMO Congress 2026.
Related stories
Universal Music Q3 revenue rises on subscription growth
M impact | EQUITY | Oct 29, 2026, 04:56 PM UTC
West Fraser to Indefinitely Curtail Production at Arkansas Sawmill, Alabama Facility
North America's largest lumber producer said it would indefinitely curtail production at an Arkansas sawmill and a wood-panel facility in Alabama.
M impact | EQUITY | Oct 29, 2026, 04:55 PM UTC
Kuwait’s HEISCO Wins $6.2 Million KNPC Refinery Order
Kuwait-listed HEISCO won a $6.2 million purchase order for a KNPC refinery project.
M impact | EQUITY | Oct 29, 2026, 04:55 PM UTC
Société Générale Completes EUR 1.5 Billion Share Buyback
Société Générale completed an extraordinary EUR 1.5 billion share buyback.
M impact | EQUITY | Oct 29, 2026, 04:54 PM UTC
Rubean Plans New-Share Placement
Rubean plans a prospectus-free placement of new shares.
L impact | EQUITY | Oct 29, 2026, 04:53 PM UTC
Manitou BF Announces Q3 2026 Revenue Release Availability
M impact | EQUITY | Oct 29, 2026, 04:53 PM UTC